other:Article Title: SARS-CoV-2 infection drives local inflammation of the intestinal epithelium in immunocompromised patients with cancer
Article Snippet: 353 354 DECLARATION OF INTERESTS 355 EL declares the following interests: EL reports honoraria and travel expenses for lab-based research talks 356 2018-21, and equipment for laboratory-based research 2018-present, Novocure, Ltd; honorarium for panel 357 discussion organized by Antidote Education for a CME module on diagnostics and treatment of HER2+ 358 gastric and colorectal cancers, funded by Daiichi-Sankyo, 2021 (honorarium donated to lab); compensation 359 for scientific review of proposed printed content, Elsevier Publishing and Johns Hopkins Press; consultant, 360 Nomocan Pharmaceuticals (no financial compensation); consultant and speaker honorarium, Boston 361 Scientific US, 2019.
Clinical Proteomics:Article Title: Clinical and molecular characteristics of Class II and III BRAF mutations in colorectal cancer.
Article Snippet: .. EL has disclosed equipment for laboratory-based research 2018-present, Novocure, Ltd; honorarium for panel discussion organized by Antidote Education for a CME module on diagnostics and treatment of HER2+ gastric and colorectal cancers, funded by Daiichi-Sankyo, 2021 (honorarium donated to lab); compensation for scientific review of proposed printed content; Elsevier Publishing and Johns Hopkins Press; consultant, Nomocan Pharmaceuticals (no financial compensation); Institutional Principal Investigator for clinical trials sponsored by Celgene, Novocure, Intima Bioscience, Inc., the National Cancer Institute, and the University of Minnesota membership in the Caris Life Sciences Precision Oncology Alliance (no financial compensation). .. A.S. has received research grants (to institution) from Merck, AstraZeneca, Bristol Myers Squibb, Exelixis, Clovis, Biontech, Astellas, Dragonfly Therapeutics, Innovent biologics, KAHR medical, Amgen, Celgene, Actuate Therapeutics, Incyte corporation, Seagen, Daiichi Sankyo, and Advisory board fees from Bristol Myers Squibb, AstraZeneca, Exelixis, Pfizer, and Daiichi Sankyo.
Article Title: Evaluation of immuno-oncologic biomarkers and β-catenin expression in response of hepatocellular carcinomas to immunotherapy
Article Snippet: .. EL disclosed the following financial relationships from the past two years: equipment for laboratory-based research 2018-present, Novocure, Ltd; honorarium for panel discussion organized by Antidote Education for a CME module on diagnostics and treatment of HER2+ gastric and colorectal cancers, funded by Daiichi-Sankyo, 2021 (honorarium donated to lab); compensation for scientific review of proposed printed content; Elsevier Publishing and Johns Hopkins Press; consultant, Nomocan Pharmaceuticals (no financial compensation); Institutional Principal Investigator for clinical trials sponsored by Celgene, Novocure, Intima Bioscience, Inc., the National Cancer Institute, and the University of Minnesota membership in the Caris Life Sciences Precision Oncology Alliance (no financial compensation). .. ESA has served as a paid consultant/advisor for Sanofi, Dendreon, Janssen Biotech, Merck, AstraZeneca, Clovis Oncology, Lilly, Bayer, and has received honoraria from Sanofi, Dendreon, Janssen Biotech, Astellas Pharma, Merck, AstraZeneca, and Clovis Oncology; has received research funding from Janssen Biotech, Johnson & Johnson, Sanofi, Dendreon, Genentech, Novartis, Astellas Pharma, Merck, AstraZeneca, Clovis Oncology, and Constellation Pharmaceuticals, a well as travel accommodations from Sanofi, and Dendreon; He is a co-inventor of a biomarker technology licensed to Qiagen.
|
